Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was somehow relaxing and refreshing, despite the increasingly tumultuous events occurring in the wider world. Nonetheless, it is time to take a deep breath and get on with the tasks at hand. On that note, we are firing up the trusty coffee kettle for another cup of stimulation — caramel vanilla cream, thank you — and assembling our to-do list. Meanwhile, here are some tidbits to get you going. Hope your day goes well, and stay safe — wear a mask. …

An experimental Eli Lilly (LLY) medicine appeared to slow the decline of patients with the early symptoms of Alzheimer’s disease, STAT writes. The results are likely to generate both excitement and debate, because the study is small — enrolling just 272 patients — and because the medicine, donanemab, is the latest in a line of similar drugs that all target the same basic chemical mechanism, known as beta amyloid. Multiple previous beta amyloid-targeting drugs have failed to reach the market, costing drug makers billions of dollars in wasted research.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!